# Efficacy and Safety of Sarecycline in Patients With Acute Ischemic Stroke After Reperfusion Therapy

> **NCT05836753** · PHASE2 · UNKNOWN · sponsor: **Beijing Tiantan Hospital** · enrollment: 120 (estimated)

## Conditions studied

- Ischemic Stroke, Acute

## Interventions

- **DRUG:** Sarecycline Tablet
- **DRUG:** Placebo tablets of Sarecycline tablets

## Key facts

- **NCT ID:** NCT05836753
- **Lead sponsor:** Beijing Tiantan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-05-07
- **Primary completion:** 2023-11
- **Final completion:** 2023-12
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2023-07-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05836753

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05836753, "Efficacy and Safety of Sarecycline in Patients With Acute Ischemic Stroke After Reperfusion Therapy". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT05836753. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*